VANCOUVER, British Columbia--(BUSINESS WIRE)--ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com) is pleased to announce that it has received excellent results from the eye inflammation study conducted by UBC (University of British Columbia). The tests conducted by Dr. Gregory-Evans MD, PhD, FRCS, FRCOphth, were designed to determine whether the powerful anti-inflammatory AAGP™ molecule could be successfully delivered to inflamed areas throughout the eye. The result demonstrated that AAGP™ penetrates through the extremely protective barriers of the eye without side effects.
